Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | bladder urothelial carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | bladder urothelial carcinoma | sensitive | Pembrolizumab | Phase II | Actionable | In a Phase II clinical study (PURE-01), neoadjuvant Keytruda (pembrolizumab) treatment in patients with muscle invasive bladder cancer with CD274 (PD-L1) combined positive scores greater than or equal to 10% resulted in a 54.3% (19/35) complete pathological response at resection compared to a 13.3% (2/15) complete pathological response at resection in patients with CD274 (PD-L1) CPS less than 10% (PMID: 30343614; NCT02736266). | 30343614 |
CD274 positive | bladder urothelial carcinoma | sensitive | Pembrolizumab | Phase II | Actionable | In a Phase II (KEYNOTE-052) trial, Keytruda (pembrolizumab) treatment resulted in objective response in 24% (89/370) of cisplatin-ineligible patients with urothelial cancer, patients with an expression of CD274 (PD-L1) over 10% demonstrated improved response, with an objective response rate of 38% (42/110) (PMID: 28967485; NCT02335424). | 28967485 |
PubMed Id | Reference Title | Details |
---|---|---|
(28967485) | First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. | Full reference... |
(30343614) | Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. | Full reference... |